Alnylam Pharmaceuticals (ALNY) Stock Buyback History
TTM buyback yield N/A.
TTM buyback yield
N/A
Shareholder yield (TTM)
N/A
5Y share count change
17.1%
TTM buyback spend
N/A
SBC coverage (TTM)
0.00x
YoY change in spend
N/A
5Y CAGR of spend
N/A
Peak year (2014)
$15.99M
Cumulative spend
$22.44M
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- Diluted share count is up 17.1% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM repurchases used about 0% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $0.00 | $348.24M | −$348.24M | 0.13B | 5.5% | — |
| 2024 | $0.00 | $272.08M | −$272.08M | 0.13B | 2.2% | — |
| 2023 | $0.00 | $221.68M | −$221.68M | 0.12B | 2.6% | — |
| 2022 | $0.00 | $230.65M | −$230.65M | 0.12B | 2.7% | — |
| 2021 | $0.00 | $165.72M | −$165.72M | 0.12B | 3.0% | — |
| 2020 | $0.00 | $139.87M | −$139.87M | 0.11B | 5.2% | — |
| 2019 | $0.00 | $174.84M | −$174.84M | 0.11B | 8.6% | — |
| 2018 | $3.47M | $157.75M | −$154.28M | 0.10B | 11.1% | 0.05% |
| 2017 | $257.00K | $92.82M | −$92.56M | 0.09B | 5.8% | 0.00% |
| 2016 | $596.00K | $75.53M | −$74.93M | 0.09B | 1.9% | 0.02% |
| 2015 | $378.00K | $45.78M | −$45.41M | 0.08B | 13.1% | 0.00% |
| 2014 | $15.99M | $33.06M | −$17.07M | 0.07B | 20.7% | 0.21% |
| 2013 | $1.39M | $20.70M | −$19.31M | 0.06B | 22.4% | 0.03% |
| 2012 | $359.00K | $12.36M | −$12.00M | 0.05B | 18.6% | 0.04% |
| 2011 | $0.00 | $16.80M | −$16.80M | 0.04B | 0.9% | — |
| 2010 | $0.00 | $19.34M | −$19.34M | 0.04B | 1.0% | — |
| 2009 | $0.00 | $20.17M | −$20.17M | 0.04B | 1.4% | — |
| 2008 | $0.00 | $18.03M | −$18.03M | 0.04B | 6.3% | — |
| 2007 | $0.00 | $14.47M | −$14.47M | 0.04B | 21.2% | — |
| 2006 | $0.00 | $8.30M | −$8.30M | 0.03B | 45.3% | — |
| 2005 | $0.00 | $0.00 | $0.00 | 0.02B | 84.7% | — |
| 2004 | $0.00 | $4.11M | −$4.11M | 0.01B | 1160.9% | — |
| 2003 | $0.00 | $0.00 | $0.00 | 0.00B | 184.5% | — |
| 2002 | $0.00 | $0.00 | $0.00 | 0.00B | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for Alnylam Pharmaceuticals (ALNY) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for Alnylam Pharmaceuticals (ALNY)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for Alnylam Pharmaceuticals (ALNY)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $0 | — | $0 | ||
| 2024 | $0 | — | $0 | ||
| 2023 | $0 | — | $0 | ||
| 2022 | $0 | — | $0 | ||
| 2021 | $0 | — | $0 | ||
| 2020 | $0 | — | $0 | ||
| 2019 | $0 | -100.0% | -$3.47M | ||
| 2018 | $3.47M | +1249.8% | +$3.21M | ||
| 2017 | $257,000 | -56.9% | -$339,000 | ||
| 2016 | $596,000 | +57.7% | +$218,000 | ||
| 2015 | $378,000 | -97.6% | -$15.61M | ||
| 2014 | $15.99M | +1051.3% | +$14.60M | ||
| 2013 | $1.39M | +286.9% | +$1.03M | ||
| 2012 | $359,000 | — | +$359,000 | ||
| 2011 | $0 | — | $0 | ||
| 2010 | $0 | — | $0 | ||
| 2009 | $0 | — | $0 | ||
| 2008 | $0 | — | $0 | ||
| 2007 | $0 | — | $0 | ||
| 2006 | $0 | — | $0 | ||
| 2005 | $0 | — | $0 | ||
| 2004 | $0 | — | $0 | ||
| 2003 | $0 | — | $0 | ||
| 2002 | $0 | — | — |
The 2025 reading of Alnylam Pharmaceuticals (ALNY) buyback spend is $0.
Through 2015–2025 (10 years), Alnylam Pharmaceuticals buyback spend delivered a -100.0% annualised rate; with a net decline across the window.
Alnylam Pharmaceuticals buyback spend peaked at $15.99M in 2014; the latest annual figure is $0 in 2025 (100.0% below peak).
Across the available history, buyback spend reached its high of $15.99M in 2014 and its low of $0 in 2002.
Within Healthcare, Alnylam Pharmaceuticals (ALNY) ranks 8th among 8 peers we track. The peer median for buyback spend is $2.75B.
Alnylam Pharmaceuticals Buyback Spend 2025: $0
Alnylam Pharmaceuticals buyback spend in 2025 was $0.
Alnylam Pharmaceuticals Buyback Spend 2024: $0
Alnylam Pharmaceuticals buyback spend in 2024 was $0.
Alnylam Pharmaceuticals Buyback Spend 2023: $0
Alnylam Pharmaceuticals buyback spend in 2023 was $0.
Alnylam Pharmaceuticals Buyback Spend 2022: $0
Alnylam Pharmaceuticals buyback spend in 2022 was $0.
Alnylam Pharmaceuticals Buyback Spend 2021: $0
Alnylam Pharmaceuticals buyback spend in 2021 was $0.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers by buyback spend
Companies in the same sector as Alnylam Pharmaceuticals, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.00×.
Capital allocation mix
How Alnylam Pharmaceuticals splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $641.34M (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from Alnylam Pharmaceuticals's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does Alnylam Pharmaceuticals buy back its own stock?
Yes, Alnylam Pharmaceuticals (ALNY) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
Is Alnylam Pharmaceuticals diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Alnylam Pharmaceuticals's share count changed?
Diluted weighted average shares changed by about 17.1% over roughly five fiscal years (annual income statement data).
What is Alnylam Pharmaceuticals's buyback spend?
Latest reported buyback spend for Alnylam Pharmaceuticals (ALNY) is $0 (period ending March 31, 2026).
What is the long-term growth rate of Alnylam Pharmaceuticals buyback spend?
Alnylam Pharmaceuticals (ALNY) buyback spend compound annual growth rate is -100.0% over the most recent 10 years available.
When did Alnylam Pharmaceuticals buyback spend hit its highest annual value?
Alnylam Pharmaceuticals buyback spend reached its highest annual value of $15.99M in 2014.
What was Alnylam Pharmaceuticals buyback spend in 2024?
Alnylam Pharmaceuticals (ALNY) buyback spend in 2024 was $0.
What was Alnylam Pharmaceuticals buyback spend in 2025?
Alnylam Pharmaceuticals (ALNY) buyback spend in 2025 was $0.
Explore more
ALNY Overview
Company profile, financial tools, and key metrics
ALNY Revenue Counter
Earns $135.94 every second. See per minute, hour, and day.
ALNY Earnings Counter
Earns $18.30 per second net profit. See per minute, hour, and day.
ALNY Economic Scale
Exceeds Aruba's GDP. Compare with world economies.
ALNY What If Invested
What if you had invested $1,000? See historical returns from any date.
ALNY How It Makes Money
Discover visual breakdown of $4.29B in revenue — where it comes from and where it goes.
ALNY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ALNY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ALNY Daily Price Character
Explosive · 50.6% historical win rate (green days). Streaks & record days.
ALNY Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.